MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Sci Rep
Prif Awduron: Jain, Ankit P., Patel, Krishna, Pinto, Sneha, Radhakrishnan, Aneesha, Nanjappa, Vishalakshi, Kumar, Manish, Raja, Remya, Patil, Arun H., Kumari, Anjali, Manoharan, Malini, Karunakaran, Coral, Murugan, Saktivel, Keshava Prasad, T. S., Chang, Xiaofei, Mathur, Premendu Prakash, Kumar, Prashant, Gupta, Ravi, Gupta, Rohit, Khanna-Gupta, Arati, Sidransky, David, Chatterjee, Aditi, Gowda, Harsha
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906491/
https://ncbi.nlm.nih.gov/pubmed/31827134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-55208-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg